Who is sponsoring NCT04927637?

NCT04927637 is sponsored by Dartmouth-Hitchcock Medical Center.

What drugs are being tested in NCT04927637?

Interventions in NCT04927637: imaging 24 hours following intravenous administration of ICG.

What condition does NCT04927637 study?

NCT04927637 studies Trauma Injury, Bone Infection.

Is NCT04927637 still recruiting?

NCT04927637 is currently completed. Last updated 27 February 2025.

Are results published for NCT04927637?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-02-27 · How we verify

NCT04927637

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ICG 24h Prior to Operative Treatment of Orthopaedic Infection

Completed Results posted Last updated 27 February 2025

What this trial tests

trial testing imaging 24 hours following intravenous administration of ICG in Trauma Injury in 2 participants. Completed in 9 March 2024.

Timeline

13 August 2021

Primary endpoint
9 March 2023

9 March 2024

Quick facts

Lead sponsor	Dartmouth-Hitchcock Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2
Start date	13 August 2021
Primary completion	9 March 2023
Estimated completion	9 March 2024
Sites	1 location across United States

Drugs / interventions tested

imaging 24 hours following intravenous administration of ICG

Conditions studied

Trauma Injury — all drugs for Trauma Injury →
Bone Infection — all drugs for Bone Infection →

Sponsor

Dartmouth-Hitchcock Medical Center

Who can join

Adults 18 to 100, any sex, with Trauma Injury or Bone Infection. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Study Design Feasibility for Preoperative ICG Perfusion Rate as a Predictability Factor for Infection: Measured as Percentage of Patients With Analyzable Data Primary · Baseline

This pilot study's objective is to preliminarily determine the study design feasibility of using a single dose of ICG given 24h preoperatively to predict recurrent infection/treatment failure. ICG Perfusion rates within the surgical site will be utilized to assess if there are any predictive measures that would indicate a higher risk of infection. Outcome measure is defined as the percentage of subjects with analyzable data.

Group	Value	95% CI
Orthopedic Infection	0

Sponsor's own description

The focus of this study is to (1) Explore variability in distribution of 24h ICG in bone and soft tissue infection (2) Evaluate the change in 24h ICG distribution from pre to post debridement (3) Preliminarily determine whether 24h ICG has the possibility predict infection / treatment failure. Patients will be administered a single, ICG, 2.5-5mg/kg dose 24 hours prior to surgery. The patient will be prepared and transported to surgery as per routine at Dartmouth-Hitchcock. ICG fluorescence images will be acquired prior to surgical debridement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Trauma Injury

Currently open trials in the same condition.

NCT07312032 — The Effects of Footplate Stiffness on Foot Loading Within Carbon Fiber Custom Dynamic Orthoses · NA · recruiting
NCT06606119 — The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma · recruiting
NCT06070350 — Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children · Phase 3 · recruiting
NCT07072286 — RELIEVED (REgionaL anesthesIa PElVic fracturEs stuDy) Study. Regional Anesthesia (RA) Techniques for Pain Management in · recruiting
NCT05721378 — Permissive Weight Bearing in Displaced Intra-articular Calcaneal Fractures · NA · recruiting

Other Dartmouth-Hitchcock Medical Center trials

Trials by the same sponsor.

NCT07325474 — Plan and Protect: Safety Planning for Teens in Rural Emergency Departments · NA · not yet recruiting
NCT07428629 — Piloting an Insomnia Treatment in Patients With Ulcerative Colitis · NA · not yet recruiting
NCT06777511 — Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients · not yet recruiting
NCT07279116 — ABY-029 Head & Neck Trial · Phase 1 · not yet recruiting
NCT07063693 — ABY-029 Glioma Trial · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04927637 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center
Last refreshed: 27 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04927637.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing